English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

ZAI Lab and Hanmi Execute a License Agreement to Develop Novel EGFR Targeted Therapy for Lung Cancer in China

Nov. 23, 2015

ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced on November 23, 2015 that they have executed a collaboration and license agreement under which ZAI Lab will acquire exclusive rights in China, Hong Kong and Macau to develop, manufacture and commercialize HM61713, a novel, third-generation EGFR targeted therapy for the treatment of EGFR mutation positive lung cancer.

The total amount agreed to be paid by ZAI Lab was $92 million as well as 10% royalties from sales.